Metagenomi Therapeutics, Inc. (MGX) stock
MGXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.69−0.02 (-3.12%)
Close on Nov 13, 2026Market cap $26.13MP/E –Yield –
Metagenomi Therapeutics operating margin
Operating margin is operating income as a percentage of revenue.
Metagenomi Therapeutics's operating margin for the twelve months ending Mar 31, 2026 was -415.5%. For fiscal 2025 it was -380.9%, against -170.0% the year before.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -380.9% | −210.9 |
| FY2024 | Dec 31, 2024 | -170.0% | +5.4 |
| FY2023 | Dec 31, 2023 | -175.4% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -1017.7% | −771.1 |
| Q1 FY2026 | Mar 31, 2026 | -1970.1% | −1296.0 |
| Q4 FY2025 | Dec 31, 2025 | -623.0% | −408.5 |
| Q3 FY2025 | Sep 30, 2025 | -263.8% | −69.4 |
| Q2 FY2025 | Jun 30, 2025 | -246.5% | −162.2 |
| Q1 FY2025 | Mar 31, 2025 | -674.1% | −413.9 |
| Q4 FY2024 | Dec 31, 2024 | -214.5% | −51.6 |
| Q3 FY2024 | Sep 30, 2024 | -194.4% | −13.3 |
| Q2 FY2024 | Jun 30, 2024 | -84.3% | +74.2 |
| Q1 FY2024 | Mar 31, 2024 | -260.2% | −53.0 |
| Q4 FY2023 | Dec 31, 2023 | -162.9% | – |
| Q3 FY2023 | Sep 30, 2023 | -181.1% | – |
| Q2 FY2023 | Jun 30, 2023 | -158.4% | – |
| Q1 FY2023 | Mar 31, 2023 | -207.2% | – |
See a number that looks wrong?